First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Titel:
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Auteur:
Janjigian, Yelena Y Shitara, Kohei Moehler, Markus Garrido, Marcelo Salman, Pamela Shen, Lin Wyrwicz, Lucjan Yamaguchi, Kensei Skoczylas, Tomasz Campos Bragagnoli, Arinilda Liu, Tianshu Schenker, Michael Yanez, Patricio Tehfe, Mustapha Kowalyszyn, Ruben Karamouzis, Michalis V Bruges, Ricardo Zander, Thomas Pazo-Cid, Roberto Hitre, Erika Feeney, Kynan Cleary, James M Poulart, Valerie Cullen, Dana Lei, Ming Xiao, Hong Kondo, Kaoru Li, Mingshun Ajani, Jaffer A